333 related articles for article (PubMed ID: 12891542)
1. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
Rahme E; Barkun AN; Toubouti Y; Bardou M
Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
Geba GP; Weaver AL; Polis AB; Dixon ME; Schnitzer TJ;
JAMA; 2002 Jan; 287(1):64-71. PubMed ID: 11754710
[TBL] [Abstract][Full Text] [Related]
3. Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.
Bardou M; Barkun AN; Ghosn J; Hudson M; Rahme E
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):880-7. PubMed ID: 15476151
[TBL] [Abstract][Full Text] [Related]
4. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
5. COX-2-specific inhibition: implications for clinical practice.
Pascucci RA
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Harley C; Wagner S
Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
[TBL] [Abstract][Full Text] [Related]
7. A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model.
Malmstrom K; Fricke JR; Kotey P; Kress B; Morrison B
Clin Ther; 2002 Oct; 24(10):1549-60. PubMed ID: 12462285
[TBL] [Abstract][Full Text] [Related]
8. [Specific inhibitors of cyclooxygenase type 2] ].
Tomasová-Studýnková J
Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
[TBL] [Abstract][Full Text] [Related]
9. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice.
Cutts C; LaCaze A; Tett S
Br J Clin Pharmacol; 2002 Nov; 54(5):522-7. PubMed ID: 12445032
[TBL] [Abstract][Full Text] [Related]
10. [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
Rioda WT; Nervetti A
Acta Biomed Ateneo Parmense; 2001; 72(3-4):55-64. PubMed ID: 11889908
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
Moore PA; Hersh EV
J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
[TBL] [Abstract][Full Text] [Related]
12. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
[TBL] [Abstract][Full Text] [Related]
13. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
14. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
15. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
Becker RV; Burke TA; McCoy MA; Trotter JP
Clin Ther; 2003 Feb; 25(2):647-62. PubMed ID: 12749519
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Spiegel BM; Targownik L; Dulai GS; Gralnek IM
Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
[TBL] [Abstract][Full Text] [Related]
17. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
Wynn RL
Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
[No Abstract] [Full Text] [Related]
18. The new NSAIDs: cox-2 inhibitors.
Capriotti T
Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
[No Abstract] [Full Text] [Related]
19. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs.
Mardini IA; FitzGerald GA
Mol Interv; 2001 Apr; 1(1):30-8. PubMed ID: 14993336
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
